Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607730 | PMC |
| http://dx.doi.org/10.5688/ajpe816120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Canakinumab is a human monoclonal anti-interleukin-1β antibody with the potential to enhance the activity of programmed death-ligand 1 inhibitors by inhibiting protumor inflammation.
Methods: CANOPY-N was a randomized, phase 2 study to evaluate safety and efficacy of neoadjuvant canakinumab (200 mg subcutaneous once every three weeks) and pembrolizumab (200 mg intravenous once every three weeks), either in combination or alone, in patients with early-stage (stage Ib-IIIa) NSCLC. The primary end point was major pathologic response (MPR) rates (≤10% of residual tumor cells) by central pathology review in the arms containing canakinumab.
A biobank for complex post-traumatic stress disorder (C-PTSD) and PTSD: study protocol for a cross-sectional study.
Eur J Psychotraumatol
December 2025
Centre for Advanced Imaging (CAI) and Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Australia.
Complex Post-Traumatic Stress Disorder (C-PTSD) is a severe mental illness recently defined in the International Classification of Diseases 11th edition. In addition to the classic PTSD symptoms of avoidance, re-experiencing, and hypervigilance, it includes disturbances in emotion regulation, negative self-concept, and interpersonal relationships. Emerging evidence suggests C-PTSD has distinct neurobiological profiles compared to PTSD, but comprehensive investigations are lacking.
View Article and Find Full Text PDFAdagrasib versus docetaxel in KRAS-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
Lancet
August 2025
State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong, Special Administrative Region, China. Electronic address:
Background: Adagrasib is a KRAS inhibitor that demonstrated promising activity against KRAS-mutated advanced non-small-cell lung cancer (NSCLC) in a phase 2 trial. Here we aimed to compare the efficacy and safety of adagrasib versus docetaxel in patients with KRAS-mutated advanced NSCLC previously treated with chemotherapy and immunotherapy.
Methods: KRYSTAL-12 is a randomised, multicentre, open-label, phase 3 trial conducted at 230 centres in 22 countries.
Development of a Neurosurgery Chatbot Using Large Language Models with Retrieval-Augmented Generation.
Stud Health Technol Inform
August 2025
School of Nursing, The Hong Kong Polytechnic University, Hong Kong.
Patient education in neurosurgery is crucial for empowering patients to make informed decisions. This study introduces NeuroBot, a chatbot leveraging Large Language Models with Retrieval-Augmented Generation to provide accurate, relevant, and context-aware responses to patient inquiries. NeuroBot's knowledge base includes curated neurosurgery resources.
View Article and Find Full Text PDFA protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions - a retrospective cohort review.
Cancer Treat Res Commun
September 2025
Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia; GenesisCare North Shore, St Leonards, NSW, Australia; GenesisCare Frenchs Forest, Frenchs Forest, NSW, Australia; Northern Clinical School, University of Sydney, St Leonards, NSW, Australia.
Purpose: Cetuximab improves survival in KRAS wildtype metastatic colorectal cancer. However, high rates of hypersensitivity reactions (HSRs) limit its use, with HSR rates up to 10-20 %. A major driver of cetuximab HSR is from pre-formed IgE antibody response to galactose-1,3-alpha-galactose (alpha-gal).
View Article and Find Full Text PDF